《美股業績》Biogen(BIIB.US)季績符預期 停售阿茲海默症新藥
美國渤健藥廠(Biogen)(BIIB.US)公佈首季業績。季度純利3.04億美元,按年跌26%。每股季度攤薄純利2.06美元,經調整後爲4.38美元,符合市場預期。季度收入25.32億美元,按年跌6%。
公司行政總裁Michel Vounatsos宣佈將會離任,公司亦宣佈暫停銷售阿茲海默症藥Aduhelm,該藥季內銷售僅280萬美元,公司同時把Aduhelm庫存減值2.75億美元。美國醫保計劃早前限制Aduhelm只能在參與臨牀測試的病人使用,公司早前亦在歐洲撤回Aduhelm的申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.